Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors

NCT02926170 is registered in ClinicalTrials.gov with Hospital Universitari Vall d'Hebron Research Institute as lead sponsor.

NCT NCT02926170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02926170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Phase
Phase 3
Overall status
Completed
Start date
March 13, 2013
Completion date
December 31, 2017
Enrollment
190 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiphospholipid syndrome